Jacobs Levy Equity Management, Inc Aldeyra Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.2 Billion
- Q2 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 634,156 shares of ALDX stock, worth $3.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
634,156
Previous 37,984
1569.53%
Holding current value
$3.4 Million
Previous $218,000
1013.76%
% of portfolio
0.01%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ALDX
# of Institutions
135Shares Held
34.9MCall Options Held
244KPut Options Held
51.6K-
Knoll Capital Management, LLC Miami, FL5.48MShares$29.3 Million14.27% of portfolio
-
Perceptive Advisors LLC New York, NY4.05MShares$21.7 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$19.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.5MShares$18.8 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT2.05MShares$11 Million1.29% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $313M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...